JP5876208B2 - 延長されたｉｎｖｉｖｏ半減期を有する第ＶＩＩａ因子−（ポリ）シアル酸結合体 - Google Patents

延長されたｉｎｖｉｖｏ半減期を有する第ＶＩＩａ因子−（ポリ）シアル酸結合体 Download PDF

Info

Publication number
JP5876208B2
JP5876208B2 JP2009541613A JP2009541613A JP5876208B2 JP 5876208 B2 JP5876208 B2 JP 5876208B2 JP 2009541613 A JP2009541613 A JP 2009541613A JP 2009541613 A JP2009541613 A JP 2009541613A JP 5876208 B2 JP5876208 B2 JP 5876208B2
Authority
JP
Japan
Prior art keywords
fviia
rfviia
molecule
life
chemically modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2009541613A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010512753A5 (enExample
JP2010512753A (ja
Inventor
ペーター テューレセク，
ペーター テューレセク，
ユルゲン ジークマン，
ユルゲン ジークマン，
フリードリッヒ シャイフリンガー，
フリードリッヒ シャイフリンガー，
ミシェル カナヴァッジオ，
ミシェル カナヴァッジオ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter Healthcare SA
Baxter International Inc
Original Assignee
Baxter Healthcare SA
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare SA, Baxter International Inc filed Critical Baxter Healthcare SA
Publication of JP2010512753A publication Critical patent/JP2010512753A/ja
Publication of JP2010512753A5 publication Critical patent/JP2010512753A5/ja
Application granted granted Critical
Publication of JP5876208B2 publication Critical patent/JP5876208B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2009541613A 2006-12-15 2007-12-14 延長されたｉｎｖｉｖｏ半減期を有する第ＶＩＩａ因子−（ポリ）シアル酸結合体 Active JP5876208B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87521706P 2006-12-15 2006-12-15
US60/875,217 2006-12-15
PCT/US2007/087553 WO2008074032A1 (en) 2006-12-15 2007-12-14 Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2012281272A Division JP2013060462A (ja) 2006-12-15 2012-12-25 延長されたｉｎｖｉｖｏ半減期を有する第ＶＩＩａ因子−（ポリ）シアル酸結合体
JP2015121340A Division JP2015163650A (ja) 2006-12-15 2015-06-16 延長されたｉｎｖｉｖｏ半減期を有する第ＶＩＩａ因子−（ポリ）シアル酸結合体

Publications (3)

Publication Number Publication Date
JP2010512753A JP2010512753A (ja) 2010-04-30
JP2010512753A5 JP2010512753A5 (enExample) 2012-01-26
JP5876208B2 true JP5876208B2 (ja) 2016-03-02

Family

ID=39119264

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2009541613A Active JP5876208B2 (ja) 2006-12-15 2007-12-14 延長されたｉｎｖｉｖｏ半減期を有する第ＶＩＩａ因子−（ポリ）シアル酸結合体
JP2012281272A Pending JP2013060462A (ja) 2006-12-15 2012-12-25 延長されたｉｎｖｉｖｏ半減期を有する第ＶＩＩａ因子−（ポリ）シアル酸結合体
JP2015121340A Withdrawn JP2015163650A (ja) 2006-12-15 2015-06-16 延長されたｉｎｖｉｖｏ半減期を有する第ＶＩＩａ因子−（ポリ）シアル酸結合体
JP2017105504A Pending JP2017141305A (ja) 2006-12-15 2017-05-29 延長されたｉｎ ｖｉｖｏ半減期を有する第ＶＩＩａ因子−（ポリ）シアル酸結合体

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2012281272A Pending JP2013060462A (ja) 2006-12-15 2012-12-25 延長されたｉｎｖｉｖｏ半減期を有する第ＶＩＩａ因子−（ポリ）シアル酸結合体
JP2015121340A Withdrawn JP2015163650A (ja) 2006-12-15 2015-06-16 延長されたｉｎｖｉｖｏ半減期を有する第ＶＩＩａ因子−（ポリ）シアル酸結合体
JP2017105504A Pending JP2017141305A (ja) 2006-12-15 2017-05-29 延長されたｉｎ ｖｉｖｏ半減期を有する第ＶＩＩａ因子−（ポリ）シアル酸結合体

Country Status (13)

Country Link
US (4) US8637007B2 (enExample)
EP (3) EP2101821B1 (enExample)
JP (4) JP5876208B2 (enExample)
CN (3) CN103804489A (enExample)
AU (1) AU2007333049B2 (enExample)
BR (1) BRPI0720282B8 (enExample)
CA (1) CA2670618C (enExample)
DK (1) DK2101821T3 (enExample)
ES (2) ES2521490T3 (enExample)
HK (1) HK1198172A1 (enExample)
PL (1) PL2101821T3 (enExample)
PT (1) PT2101821E (enExample)
WO (1) WO2008074032A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7985839B2 (en) 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
KR20080108147A (ko) 2006-03-31 2008-12-11 백스터 인터내셔널 인코포레이티드 페질화된 인자 ｖｉｉｉ
US7982010B2 (en) 2006-03-31 2011-07-19 Baxter International Inc. Factor VIII polymer conjugates
EP2101821B1 (en) 2006-12-15 2014-08-13 Baxter International Inc. Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life
US20100081187A1 (en) * 2007-04-26 2010-04-01 Griffith Michael J Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same
MX2009013682A (es) * 2007-06-26 2010-08-31 Baxter Int Enlazador de fmoc polimerico hidrolizable.
AU2009305612B2 (en) * 2008-10-17 2015-05-21 Takeda Pharmaceutical Company Limited Modified blood factors comprising a low degree of water soluble polymer
JP2012518029A (ja) 2009-02-19 2012-08-09 ノヴォ・ノルディスク・アー／エス 第ｖｉｉｉ因子の修飾
US12203113B2 (en) 2009-07-09 2025-01-21 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
JP5909755B2 (ja) 2009-07-27 2016-04-27 リポクセン テクノロジーズ リミテッド 非血液凝固タンパク質の糖ポリシアル酸化
PL2459224T3 (pl) 2009-07-27 2017-08-31 Baxalta GmbH Koniugaty białka związanego z krzepnięciem krwi
MX2012001207A (es) * 2009-07-27 2012-05-08 Baxter Int Conjugados proteicos de coagulacion sanguínea.
ES2600879T3 (es) 2009-11-13 2017-02-13 Grifols Therapeutics Inc. Preparaciones que contienen el factor de Von Willebrand (FvW) y procedimientos, kits y utilizaciones relacionados con las mismas
JP5914363B2 (ja) 2010-02-16 2016-05-11 ノヴォ ノルディスク アー／エス 低減されたｖｗｆ結合を有する因子ｖｉｉｉ分子
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
NZ605972A (en) 2010-07-30 2015-04-24 Baxter Healthcare Sa Nucleophilic catalysts for oxime linkage
PL2654794T3 (pl) 2010-12-22 2020-07-27 Baxalta GmbH Materiały i sposoby sprzęgania rozpuszczalnej w wodzie pochodnej kwasu tłuszczowego z białkiem
BR112014006684A2 (pt) 2011-09-23 2017-03-28 Novo Nordisk As análogos de glucagon
CN104411335A (zh) 2012-04-16 2015-03-11 剑桥生物制药专利有限公司 优化的皮下治疗药剂
AU2013204754C1 (en) 2012-05-16 2018-10-11 Takeda Pharmaceutical Company Limited Nucleophilic Catalysts for Oxime Linkage
EP2906247A1 (en) 2012-10-15 2015-08-19 Novo Nordisk Health Care AG Factor vii conjugates
DK2938351T3 (da) * 2012-12-24 2019-09-23 Coagulant Therapeutics Corp Faktor vii-polypeptider med kortvarig virkning
WO2014170496A1 (en) 2013-04-18 2014-10-23 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use
WO2015055692A1 (en) 2013-10-15 2015-04-23 Novo Nordisk Health Care Ag Coagulation factor vii polypeptides
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
AR099340A1 (es) * 2014-02-12 2016-07-13 Novo Nordisk As Conjugados del factor de coagulación ix
EP3129408A4 (en) * 2014-04-11 2018-04-25 CSL Limited Half-life extended factor fviia protein for prevention and treatment of bleeding and dosing regimens therefor
JP2017525656A (ja) 2014-06-04 2017-09-07 ノヴォ ノルディスク アー／エス 医療用のｇｌｐ−１／グルカゴン受容体コアゴニスト
US12459982B2 (en) 2014-12-10 2025-11-04 Opko Biologistics Ltd. Methods of producing long acting CTP-modified growth hormone polypeptides
JP2015155469A (ja) * 2015-06-01 2015-08-27 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ 第ｆｖｉｉｉ因子ポリマー結合体
IL315314A (en) * 2016-07-11 2024-10-01 Opko Biologics Ltd Long-acting coagulation factors and methods of producing same
JP2018115170A (ja) * 2018-03-02 2018-07-26 バクスアルタ ゲーエムベーハー 第ｆｖｉｉｉ因子ポリマー結合体
US20220105190A1 (en) * 2019-02-04 2022-04-07 Lipoxen Technologies Limited Methods of using glycopolysialylated therapeutic proteins

Family Cites Families (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3487890A (en) 1967-04-14 1970-01-06 Boyles Bros Drilling Co Core drilling system
US3847890A (en) 1971-11-01 1974-11-12 A Green Acidic monosaccharide-substituted proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4970300A (en) 1985-02-01 1990-11-13 New York University Modified factor VIII
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5250421A (en) 1986-01-03 1993-10-05 Genetics Institute, Inc. Method for producing factor VIII:C-type proteins
US5198349A (en) 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
US5153265A (en) 1988-01-20 1992-10-06 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US4966999A (en) 1988-06-07 1990-10-30 Cytogen Corporation Radiohalogenated compounds for site specific labeling
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
SE466754B (sv) 1990-09-13 1992-03-30 Berol Nobel Ab Saett att kovalent binda biopolymerer till hydrofila ytor
EP0513332A4 (en) 1990-11-14 1993-03-17 Cargill, Incorporated Conjugates of poly(vinylsaccharide) with proteins for the stabilization of proteins
JPH06506217A (ja) 1991-03-18 1994-07-14 エンゾン，インコーポレーテッド ポリペプチドまたはグリコポリペプチドとポリマーとのヒドラジン含有結合体
US5846951A (en) 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
GB9112212D0 (en) * 1991-06-06 1991-07-24 Gregoriadis Gregory Pharmaceutical compositions
US6037452A (en) 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
AU5098193A (en) 1992-09-01 1994-03-29 Berlex Laboratories, Inc. Glycolation of glycosylated macromolecules
HU220194B (hu) 1992-10-02 2001-11-28 Genetics Institute Inc. Koagulációs faktor VIII-at tartalmazó készítmény és eljárás előállítására
NZ250375A (en) 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5298643A (en) 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
FR2700268B1 (fr) 1993-01-13 1995-03-31 Lvmh Rech Composition cosmétique ou pharmaceutique, notamment dermatologique, contenant un extrait de Vismia.
WO1994015625A1 (en) 1993-01-15 1994-07-21 Enzon, Inc. Factor viii - polymeric conjugates
AU7097094A (en) 1993-06-01 1994-12-20 Enzon, Inc. Carbohydrate-modified polymer conjugates with erythropoietic activity
US5621039A (en) 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
CA2204726A1 (en) 1994-11-09 1996-12-27 Robin E. Offord Functionalized polymers for site-specific attachment
WO1996040731A1 (en) 1995-06-07 1996-12-19 Mount Sinai School Of Medicine Of The City University Of New York Pegylated modified proteins
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
AU5773798A (en) 1997-01-29 1998-08-18 Polymasc Pharmaceuticals Plc Pegylation process
EP0981548A4 (en) 1997-04-30 2005-11-23 Enzon Inc GLYCOSYLATABLE SINGLE CHAIN ANTIGEN-BINDING PROTEINS, MANUFACTURE AND USE THEREOF
US6183738B1 (en) 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
WO2001082943A2 (en) 2000-05-03 2001-11-08 Novo Nordisk A/S Subcutaneous administration of coagulation factor vii
AU2051899A (en) 1997-12-03 1999-06-16 Roche Diagnostics Gmbh Method for preparing polypeptides with appropriate glycosilation
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
ATE283034T1 (de) 1998-04-27 2004-12-15 Opperbas Holding Bv Pharmazeutische zusammensetzungen enthaltend faktor viii und neutrale liposomen
JP2002528562A (ja) 1998-08-28 2002-09-03 グリフォン サイエンシーズ 長さのばらつきが小さいポリアミド連鎖、その連鎖の製造方法およびその連鎖とタンパク質の複合体
CN101062419B (zh) 1998-10-16 2016-06-29 生物基因Ma公司 干扰素-β-1a的聚合物缀合物及其使用
DE19852729A1 (de) 1998-11-16 2000-05-18 Werner Reutter Rekombinante Glycoproteine, Verfahren zu ihrer Herstellung, sie enthaltende Arzneimittel und ihre Verwendung
CN101810854A (zh) 1999-02-22 2010-08-25 巴克斯特国际公司 新的无白蛋白的因子viii制剂
US6531122B1 (en) 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
CN1309423C (zh) 1999-11-12 2007-04-11 马克西根控股公司 干扰素γ偶联物
ATE428445T1 (de) 2000-02-11 2009-05-15 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
EP1282693B1 (en) 2000-05-03 2010-10-20 Novo Nordisk Health Care AG Human coagulation factor vii variants
CA2414076A1 (en) 2000-06-08 2001-12-13 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
US6423826B1 (en) 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
US7118737B2 (en) 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
JP4361728B2 (ja) 2000-09-13 2009-11-11 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ヒト凝固因子ｖｉｉ変異型
EP2311943A3 (en) * 2000-10-02 2011-05-04 Novo Nordisk Health Care AG Factor VII glycoforms
WO2002032957A1 (en) 2000-10-16 2002-04-25 Chugai Seiyaku Kabushiki Kaisha Peg-modified erythropoietin
ES2432967T3 (es) 2001-03-22 2013-12-05 Novo Nordisk Health Care Ag Derivados del Factor VII de coagulación
US6913915B2 (en) 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
US8008252B2 (en) * 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
EP2305313B1 (en) 2001-10-10 2014-03-26 ratiopharm GmbH Remodelling and glycoconjugation of interferon-alpha (IFNa)
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
EP1446438A2 (en) 2001-11-07 2004-08-18 Nektar Therapeutics Al, Corporation Branched polymers and their conjugates
WO2003045980A2 (en) 2001-11-28 2003-06-05 Neose Technologies, Inc. Glycopeptide remodeling using amidases
CA2468295C (en) 2001-11-28 2010-08-03 Neose Technologies, Inc. Glycoprotein remodeling using endoglycanases
DE60336555D1 (de) 2002-06-21 2011-05-12 Novo Nordisk Healthcare Ag Pegylierte glykoformen von faktor vii
CA2490360A1 (en) * 2002-06-21 2003-12-31 Novo Nordisk Health Care Ag Pegylated factor vii glycoforms
US7122189B2 (en) 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
US7087229B2 (en) 2003-05-30 2006-08-08 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
WO2004024761A1 (en) 2002-09-11 2004-03-25 Fresenius Kabi Deutschland Gmbh Hasylated polypeptides, especially hasylated erythropoietin
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
EP1578841B2 (en) 2002-12-31 2016-10-12 Nektar Therapeutics AL, Corporation Maleamic acid polymer derivatives and their bioconjugates
CN100343304C (zh) 2002-12-31 2007-10-17 尼克塔治疗亚拉巴马公司 水解稳定的马来酰亚胺封端的聚合物
KR101085375B1 (ko) 2003-02-26 2011-11-21 넥타르 테라퓨틱스 중합체-인자 ⅷ 부분 콘쥬게이트
US7691603B2 (en) * 2003-04-09 2010-04-06 Novo Nordisk A/S Intracellular formation of peptide conjugates
BRPI0412671A (pt) 2003-08-08 2006-10-03 Fresenius Kabi De Gmbh conjugados de um polìmero e uma proteìna ligados por um grupo de ligação de oxima
WO2005014035A2 (en) 2003-08-08 2005-02-17 Novo Nordisk Health Care Ag Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
KR101113726B1 (ko) 2003-08-12 2012-02-27 리폭센 테크놀로지즈 리미티드 단백질 유도 및 컨쥬게이션용 시알산 유도체
EP1654289B1 (en) 2003-08-12 2007-10-03 Lipoxen Technologies Limited Polysialic acid derivatives
WO2005032581A2 (en) 2003-10-07 2005-04-14 Novo Nordisk Health Care Ag Hybrid molecules having factor vii/viia activity
WO2005055950A2 (en) 2003-12-03 2005-06-23 Neose Technologies, Inc. Glycopegylated factor ix
ES2560657T3 (es) 2004-01-08 2016-02-22 Ratiopharm Gmbh Glicosilación con unión en O de péptidos G-CSF
KR100651220B1 (ko) 2004-06-29 2006-11-29 씨제이 주식회사 Ｌ-메씨오닌 생산 균주 및 상기 균주를 이용한ｌ-메씨오닌의 생산방법
EP1786379A2 (en) 2004-07-14 2007-05-23 Mali Arel Feeding bottles
US20090292110A1 (en) 2004-07-23 2009-11-26 Defrees Shawn Enzymatic modification of glycopeptides
WO2006013202A2 (en) 2004-08-02 2006-02-09 Novo Nordisk Health Care Ag Conjugation of fvii
EP1776389B1 (en) * 2004-08-12 2016-06-29 Lipoxen Technologies Limited Sialic acid derivatives
ES2821832T3 (es) 2004-11-12 2021-04-27 Bayer Healthcare Llc Modificación de FVIII dirigida al sitio
JP5022231B2 (ja) * 2004-12-27 2012-09-12 バクスター・インターナショナル・インコーポレイテッド ポリマー−フォンビルブラント因子結合体
EP1838332A1 (en) 2005-01-06 2007-10-03 Neose Technologies, Inc. Glycoconjugation using saccharyl fragments
EP1853634B1 (en) * 2005-02-23 2016-08-10 Lipoxen Technologies Limited Activated sialic acid derivatives for protein derivatisation and conjugation
AU2006222187A1 (en) * 2005-03-11 2006-09-14 Fresenius Kabi Deutschland Gmbh Production of bioactive glycoproteins from inactive starting material by conjugation with hydroxyalkylstarch
JP5216580B2 (ja) 2005-05-25 2013-06-19 ノヴォ ノルディスク アー／エス グリコペグ化第ｉｘ因子
US8633300B2 (en) 2005-06-17 2014-01-21 Novo Nordisk Healthcare Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
EP1919498A2 (en) 2005-08-26 2008-05-14 Maxygen Holdings Ltd. Liquid factor vii composition
EP1962907A2 (en) 2005-12-21 2008-09-03 Wyeth a Corporation of the State of Delaware Protein formulations with reduced viscosity and uses thereof
US7985839B2 (en) 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
KR20080108147A (ko) 2006-03-31 2008-12-11 백스터 인터내셔널 인코포레이티드 페질화된 인자 ｖｉｉｉ
US7982010B2 (en) 2006-03-31 2011-07-19 Baxter International Inc. Factor VIII polymer conjugates
US20090285780A1 (en) 2006-05-24 2009-11-19 Chyi Lee Peg linker compounds and biologically active conjugates thereof
JP2007319283A (ja) * 2006-05-31 2007-12-13 Nippon Sherwood Medical Industries Ltd 医療用バッグ
US7939632B2 (en) 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
ES2565180T3 (es) 2006-07-13 2016-04-01 Serum Institute Of India Ltd, Proceso para la preparación de ácido polisiálico de gran pureza
JP5096466B2 (ja) 2006-07-25 2012-12-12 リポクセン テクノロジーズ リミテッド Ｎ末端ポリシアリル化
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
EP2101821B1 (en) * 2006-12-15 2014-08-13 Baxter International Inc. Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life
WO2008081024A1 (en) 2007-01-03 2008-07-10 Novo Nordisk Health Care Ag Subcutaneous administration of coagulation factor viia-related popypeptdes
WO2008119815A1 (en) 2007-04-02 2008-10-09 Novo Nordisk A/S Subcutaneous administration of coagulation factor ix
MX2009013682A (es) 2007-06-26 2010-08-31 Baxter Int Enlazador de fmoc polimerico hidrolizable.
JP5702600B2 (ja) 2007-07-03 2015-04-15 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド オリゴシアル酸誘導体、製造方法および免疫学的使用
ES2597849T3 (es) 2007-10-09 2017-01-23 Polytherics Limited Proteínas y péptidos conjugados novedosos
JP5647899B2 (ja) 2008-01-08 2015-01-07 ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ オリゴサッカリルトランスフェラーゼを使用するポリペプチドの複合糖質化
KR101582841B1 (ko) 2008-02-27 2016-01-11 노보 노르디스크 에이/에스 콘쥬게이트된 인자 ｖｉｉｉ 분자
MX2010011672A (es) 2008-04-24 2011-03-02 Celtic Pharma Peg Ltd Conjugados del factor ix con vidas medias extendidas.
CN102065899A (zh) 2008-05-23 2011-05-18 诺沃-诺迪斯克保健股份有限公司 含有高浓度的芳香族防腐剂的peg-官能化的丝氨酸蛋白酶的制剂
CN102083459A (zh) 2008-05-23 2011-06-01 诺沃-诺迪斯克保健股份有限公司 包括含有peg化的gla-结构域的蛋白质的低粘度组合物
AU2009256093A1 (en) 2008-06-04 2009-12-10 Bayer Healthcare Llc FVIII muteins for treatment of von Willebrand disease
DK2374481T3 (en) 2008-07-21 2016-02-01 Polytherics Ltd New reagents and methods for the conjugation of biological molecules
KR20110093775A (ko) 2008-11-03 2011-08-18 바이엘 헬스케어 엘엘씨 혈우병 치료 방법
WO2010083536A1 (en) 2009-01-19 2010-07-22 Bayer Healthcare Llc Protein conjugate having an endopeptidase-cleavable bioprotective moiety
JP2012518029A (ja) 2009-02-19 2012-08-09 ノヴォ・ノルディスク・アー／エス 第ｖｉｉｉ因子の修飾
WO2010100430A1 (en) 2009-03-04 2010-09-10 Polytherics Limited Conjugated proteins and peptides
US20100330033A1 (en) 2009-04-16 2010-12-30 Nian Wu Protein-carrier conjugates
GB0908393D0 (en) 2009-05-15 2009-06-24 Almac Sciences Scotland Ltd Labelling method
MX2012001207A (es) 2009-07-27 2012-05-08 Baxter Int Conjugados proteicos de coagulacion sanguínea.
JP5909755B2 (ja) 2009-07-27 2016-04-27 リポクセン テクノロジーズ リミテッド 非血液凝固タンパク質の糖ポリシアル酸化
PE20121643A1 (es) 2009-07-31 2012-11-25 Bayer Healthcare Llc Polipeptidos del factor ix modificados y usos de los mismos
DE102009028526A1 (de) 2009-08-13 2011-02-24 Leibniz-Institut Für Polymerforschung Dresden E.V. Verfahren zur Modifikation und Funktionalisierung von Sacchariden
WO2011037896A2 (en) 2009-09-25 2011-03-31 Vybion, Inc. Polypeptide modification
WO2011064247A1 (en) 2009-11-24 2011-06-03 Novo Nordisk Health Care Ag Method of purifying pegylated proteins
JP5914363B2 (ja) 2010-02-16 2016-05-11 ノヴォ ノルディスク アー／エス 低減されたｖｗｆ結合を有する因子ｖｉｉｉ分子
GB201007357D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
EP2640483A1 (en) 2010-11-15 2013-09-25 Biogen Idec Inc. Enrichment and concentration of select product isoforms by overloaded bind and elute chromatography
HUE043763T2 (hu) 2011-07-08 2019-09-30 Bioverativ Therapeutics Inc VIII-as faktor kiméra és hibrid polipeptidek, és azok alkalmazási eljárásai

Also Published As

Publication number Publication date
US8637007B2 (en) 2014-01-28
CN101557830B (zh) 2016-06-08
PL2101821T3 (pl) 2015-01-30
EP2532369B1 (en) 2017-11-01
CN105838699A (zh) 2016-08-10
EP2101821A1 (en) 2009-09-23
DK2101821T3 (da) 2014-10-06
BRPI0720282B1 (pt) 2021-03-30
EP3323430A1 (en) 2018-05-23
AU2007333049A1 (en) 2008-06-19
PT2101821E (pt) 2014-10-03
CA2670618C (en) 2016-10-04
JP2013060462A (ja) 2013-04-04
WO2008074032A1 (en) 2008-06-19
ES2655639T3 (es) 2018-02-21
EP2101821B1 (en) 2014-08-13
JP2017141305A (ja) 2017-08-17
US20110064714A1 (en) 2011-03-17
US20140186323A1 (en) 2014-07-03
AU2007333049B2 (en) 2014-02-20
US20160129121A1 (en) 2016-05-12
US20080221032A1 (en) 2008-09-11
BRPI0720282A2 (pt) 2014-01-28
JP2015163650A (ja) 2015-09-10
EP2532369A3 (en) 2013-01-02
CA2670618A1 (en) 2008-06-19
CN101557830A (zh) 2009-10-14
HK1198172A1 (en) 2015-03-13
EP2532369A2 (en) 2012-12-12
US10251941B2 (en) 2019-04-09
ES2521490T3 (es) 2014-11-12
BRPI0720282B8 (pt) 2021-05-25
JP2010512753A (ja) 2010-04-30
CN103804489A (zh) 2014-05-21

Similar Documents

Publication Publication Date Title
JP5876208B2 (ja) 延長されたｉｎｖｉｖｏ半減期を有する第ＶＩＩａ因子−（ポリ）シアル酸結合体
JP7054407B2 (ja) オキシム連結のための求核触媒
JP5908401B2 (ja) 血液凝固タンパク質複合体
US11040109B2 (en) Blood coagulation protein conjugates
TW201835109A (zh) 具有增加之半衰期之治療蛋白質及其製備方法
HK1229229A (zh) 凝血蛋白綴合物
HK1229229A1 (en) Blood coagulation protein conjugates

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20121225

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131025

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20131210

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20140221

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140908

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140911

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141010

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141016

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20141110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150616

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151110

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160121

R150 Certificate of patent or registration of utility model

Ref document number: 5876208

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250